{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:38:13Z","timestamp":1761154693493},"reference-count":79,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hodgkin\u2019s lymphoma is a unique neoplasm of B lymphocytes. Recent data provide new understandings of the pathogenesis and options for staging and therapy of the disease. Three specific topics are addressed in this chapter.<\/jats:p>\n               <jats:p>In Section I, Dr. Richard Ambinder reviews implications of the relationship of Epstein-Barr virus (EBV) and Hodgkin\u2019s lymphoma. This relation includes varying geographic epidemiologic associations, including varying associations with the clinical syndrome of infectious mononucleosis. There are plausible mechanisms, including processes initiated by viral proteins, by which EBV might lead to tumorigenesis. These mechanisms include promotion of genetic instability and alteration of normal processes of apoptosis. In addition to an epidemiologic association and potential role in pathogenesis, viral antigens may pose theoretical targets for anti-cancer therapies, including vaccination.<\/jats:p>\n               <jats:p>In Section II, Dr. Sigrid Stroobants describes the potential role of positron emission tomographic (PET) scanning. By assessing differences in the metabolic activities of cancer cells, PET scanning may be superior to computerized tomographic scanning, which is limited to showing structural anatomical abnormalities. In patients with Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma, PET scanning has been tested as an initial staging tool, to assess the rate of therapeutic response from a prognostic perspective, and to differentiate residual tumor from fibrotic masses in patients who have completed therapy. Particularly in assessing the nature of a residual mass seen with other post-therapeutic imaging modalities, PET scanning may provide unique information; very high negative predictive values have been reported. However, before this technology can be recommended for incorporation into standard management, properly conducted prospective trials are required to better evaluate the clinical utility of PET with respect to eventual patient outcomes.<\/jats:p>\n               <jats:p>In Section III, Dr. Ralph Meyer reviews current data regarding the management of patients with limited-stage Hodgkin\u2019s lymphoma. Over the past decade, standard treatment has evolved to consist of combined-modality therapy that includes an abbreviated course of chemotherapy and involved-field radiation. As this therapy continues to include radiation therapy, patients will remain at risk of long-term toxicities that include the development of second cancers and cardiovascular events. These \u201clate-effects\u201d now account for more deaths than those attributed to progressive Hodgkin\u2019s lymphoma. Comparative data testing the role of chemotherapy alone are now available and demonstrate that omission of radiation therapy results in small but statistically significant reduction in disease control, but no detectable differences in overall survival. Further follow-up will clarify whether chemotherapy alone is the preferred treatment option; at present patients should be informed of the trade-offs involved in choosing between this option and combined modality therapy.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.184","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"184-202","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Hodgkin\u2019s Lymphoma: Evolving Concepts with Implications for Practice"],"prefix":"10.1182","volume":"2004","author":[{"given":"Ralph M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid","family":"Stroobants","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021215282454700_R1","doi-asserted-by":"crossref","unstructured":"Kuppers R. Molecular biology of Hodgkin\u2019s lymphoma. Adv Cancer Res. 2002;84:277\u2013312.","DOI":"10.1016\/S0065-230X(02)84009-X"},{"key":"2020021215282454700_R2","doi-asserted-by":"crossref","unstructured":"Ambinder R. Infection and lymphoma. N Engl J Med. 2003;349:1309\u20131311.","DOI":"10.1056\/NEJMp030083"},{"key":"2020021215282454700_R3","doi-asserted-by":"crossref","unstructured":"Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89\u201394.","DOI":"10.1056\/NEJMoa013376"},{"key":"2020021215282454700_R4","doi-asserted-by":"crossref","unstructured":"Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349:1324\u20131332.","DOI":"10.1056\/NEJMoa023141"},{"key":"2020021215282454700_R5","doi-asserted-by":"crossref","unstructured":"Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375\u2013382.","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T"},{"key":"2020021215282454700_R6","doi-asserted-by":"crossref","unstructured":"Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117:259\u2013267.","DOI":"10.1309\/MMAU-0QYH-7BHA-W8C2"},{"key":"2020021215282454700_R7","doi-asserted-by":"crossref","unstructured":"Glaser SL, Gulley ML, Borowitz MJ, et al. Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma. 2004;45:489\u2013497.","DOI":"10.1080\/1042819032000141310"},{"key":"2020021215282454700_R8","doi-asserted-by":"crossref","unstructured":"He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF\/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol2003;171:5215\u20135224.","DOI":"10.4049\/jimmunol.171.10.5215"},{"key":"2020021215282454700_R9","doi-asserted-by":"crossref","unstructured":"Takada K. Role of Epstein-Barr virus in Burkitt\u2019s lymphoma. Curr Top Microbiol Immunol. 2001;258:141\u2013151.","DOI":"10.1007\/978-3-642-56515-1_9"},{"key":"2020021215282454700_R10","doi-asserted-by":"crossref","unstructured":"Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the greater San Francisco Bay area, 1988\u20131998. Cancer. 2003;98:300\u2013309.","DOI":"10.1002\/cncr.11459"},{"key":"2020021215282454700_R11","doi-asserted-by":"crossref","unstructured":"Benharroch D, Shemer-Avni Y, Myint YY, et al. Measles virus: evidence of an association with Hodgkin\u2019s disease. Br J Cancer. 2004;91:572\u2013579.","DOI":"10.1038\/sj.bjc.6601900"},{"key":"2020021215282454700_R12","doi-asserted-by":"crossref","unstructured":"Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A. 1998;95:11963\u201311968.","DOI":"10.1073\/pnas.95.20.11963"},{"key":"2020021215282454700_R13","doi-asserted-by":"crossref","unstructured":"Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin\u2019s lymphoma. Blood. 2003;102:4166\u20134178.","DOI":"10.1182\/blood-2003-04-1018"},{"key":"2020021215282454700_R14","doi-asserted-by":"crossref","unstructured":"Swanson-Mungerson M, Ikeda M, Lev L, Longnecker R, Portis T. Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases. J Antimicrob Chemother. 2003;52:152\u2013154.","DOI":"10.1093\/jac\/dkg306"},{"key":"2020021215282454700_R15","unstructured":"Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63:2028\u20132032."},{"key":"2020021215282454700_R16","doi-asserted-by":"crossref","unstructured":"Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461\u20132470.","DOI":"10.1056\/NEJMoa032260"},{"key":"2020021215282454700_R17","doi-asserted-by":"crossref","unstructured":"Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood. 2000;95:241\u2013248.","DOI":"10.1182\/blood.V95.1.241"},{"key":"2020021215282454700_R18","unstructured":"Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin\u2019s disease patients: implications for a T-cell-based therapy. Cancer Res. 2001;61:6219\u20136226."},{"key":"2020021215282454700_R19","doi-asserted-by":"crossref","unstructured":"Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin\u2019s disease. Blood. 1998;92:2477\u20132483.","DOI":"10.1182\/blood.V92.7.2477"},{"key":"2020021215282454700_R20","doi-asserted-by":"crossref","unstructured":"Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin\u2019s disease. Blood. 1998;91:2925\u20132934.","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934"},{"key":"2020021215282454700_R21","doi-asserted-by":"crossref","unstructured":"Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875\u20133876.","DOI":"10.1182\/blood-2002-09-2778"},{"key":"2020021215282454700_R22","doi-asserted-by":"crossref","unstructured":"Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30 Suppl 1:S82\u201388.","DOI":"10.1007\/s00259-003-1165-6"},{"key":"2020021215282454700_R23","doi-asserted-by":"crossref","unstructured":"Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Am J Med. 2002;112:262\u2013268.","DOI":"10.1016\/S0002-9343(01)01117-2"},{"key":"2020021215282454700_R24","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45:85\u201392.","DOI":"10.1080\/1042819031000149430"},{"key":"2020021215282454700_R25","unstructured":"Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40:1407\u20131413."},{"key":"2020021215282454700_R26","doi-asserted-by":"crossref","unstructured":"Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340\u20133346.","DOI":"10.1182\/blood.V91.9.3340"},{"key":"2020021215282454700_R27","doi-asserted-by":"crossref","unstructured":"Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET\/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325\u2013329.","DOI":"10.1007\/s00259-003-1375-y"},{"key":"2020021215282454700_R28","doi-asserted-by":"crossref","unstructured":"Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin\u2019s lymphoma. Br J Cancer. 2004;90:620\u2013625.","DOI":"10.1038\/sj.bjc.6601561"},{"key":"2020021215282454700_R29","doi-asserted-by":"crossref","unstructured":"Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302\u2013310.","DOI":"10.1002\/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4"},{"key":"2020021215282454700_R30","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin\u2019s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272\u2013278.","DOI":"10.1046\/j.1365-2141.2001.03169.x"},{"key":"2020021215282454700_R31","doi-asserted-by":"crossref","unstructured":"Dittmann H, Sokler M, Kollmannsberger C, et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin\u2019s lymphoma. Oncol Rep. 2001;8:1393\u20131399.","DOI":"10.3892\/or.8.6.1393"},{"key":"2020021215282454700_R32","doi-asserted-by":"crossref","unstructured":"Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Br J Haematol. 2001;115:793\u2013800.","DOI":"10.1046\/j.1365-2141.2001.03147.x"},{"key":"2020021215282454700_R33","doi-asserted-by":"crossref","unstructured":"Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930\u20132934.","DOI":"10.1182\/blood.V98.10.2930"},{"key":"2020021215282454700_R34","doi-asserted-by":"crossref","unstructured":"de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin\u2019s lymphoma. Ann Oncol. 2001;12:29\u201337.","DOI":"10.1023\/A:1008357126404"},{"key":"2020021215282454700_R35","doi-asserted-by":"crossref","unstructured":"Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:307\u2013315.","DOI":"10.1016\/S0360-3016(03)00599-6"},{"key":"2020021215282454700_R36","unstructured":"Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin\u2019s disease for posttreatment evaluation. J Nucl Med. 2003;44:1225\u20131231."},{"key":"2020021215282454700_R37","doi-asserted-by":"crossref","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin\u2019s disease. Ann Oncol. 2003;14:123\u2013130.","DOI":"10.1093\/annonc\/mdg011"},{"key":"2020021215282454700_R38","unstructured":"Brink I, Reinhardt MJ, Hoegerle S, et al. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med. 2001;42:591\u2013595."},{"key":"2020021215282454700_R39","unstructured":"Dobert N, Menzel C, Hamscho N, et al. Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Q J Nucl Med. 2004;48:33\u201338."},{"key":"2020021215282454700_R40","doi-asserted-by":"crossref","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med. 1998;339:1506\u20131514.","DOI":"10.1056\/NEJM199811193392104"},{"key":"2020021215282454700_R41","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682\u2013688.","DOI":"10.1007\/s00259-003-1120-6"},{"key":"2020021215282454700_R42","unstructured":"Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin\u2019s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464\u20134471."},{"key":"2020021215282454700_R43","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin\u2019s lymphoma. Haematologica. 2000;85:613\u2013618."},{"key":"2020021215282454700_R44","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Timothy AR, O\u2019Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin\u2019s lymphoma-comparison with CT. Leuk Lymphoma. 2000;39:543\u2013553.","DOI":"10.3109\/10428190009113384"},{"key":"2020021215282454700_R45","unstructured":"Mikhaeel NG, Mainwaring P, Nunan T, Timothy AR. Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma (abstract). Ann Oncol. 2002;13 (suppl 2):21."},{"key":"2020021215282454700_R46","unstructured":"Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin\u2019s disease. J Nucl Med. 2002;43:1018\u20131027."},{"key":"2020021215282454700_R47","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2002;13:1356\u20131363.","DOI":"10.1093\/annonc\/mdf256"},{"key":"2020021215282454700_R48","doi-asserted-by":"crossref","unstructured":"Zijlstra JM, Hoekstra OS, Raijmakers PG, et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin\u2019s lymphoma. Br J Haematol. 2003;123:454\u2013462.","DOI":"10.1046\/j.1365-2141.2003.04617.x"},{"key":"2020021215282454700_R49","doi-asserted-by":"crossref","unstructured":"Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 2002;16:260\u2013267.","DOI":"10.1038\/sj.leu.2402342"},{"key":"2020021215282454700_R50","doi-asserted-by":"crossref","unstructured":"Cremerius U, Fabry U, Wildberger JE, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2002;30:103\u2013111.","DOI":"10.1038\/sj.bmt.1703607"},{"key":"2020021215282454700_R51","doi-asserted-by":"crossref","unstructured":"Filmont JE, Czernin J, Yap C, Silverman DH, et al Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 2003;124:608\u2013613.","DOI":"10.1378\/chest.124.2.608"},{"key":"2020021215282454700_R52","doi-asserted-by":"crossref","unstructured":"Schot B, van Imhoff G, Pruim J, et al. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol. 2003;123:282\u2013287.","DOI":"10.1046\/j.1365-2141.2003.04593.x"},{"key":"2020021215282454700_R53","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53\u201359.","DOI":"10.1182\/blood-2002-12-3842"},{"key":"2020021215282454700_R54","unstructured":"Canadian Cancer Statistics 2004. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial\/Territorial Cancer Registries, Health Canada. www.cancer.ca"},{"key":"2020021215282454700_R55","unstructured":"Henry-Amar M, Aeppli DM, Anderson J, et al. Long term survival and study of causes of death. In: Somers R, Henry-Amar M, Meerwaldt JK, Carde P, eds. Treatment Strategy in Hodgkin\u2019s Disease. London: John Libbey and Co; 1990: 381\u2013418."},{"key":"2020021215282454700_R56","unstructured":"Sieber M, Franklin J, Tesch H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin\u2019s disease: results of the German Hodgkin\u2019s Lymphoma Study Group (GHSG) Trial HD7 [abstract]. Blood. 2002;100:93a."},{"key":"2020021215282454700_R57","unstructured":"Meyer RM, Gospodarowicz M, Connors J, et al. A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin\u2019s disease: the HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06) [abstract]. Blood. 2003;102:26a."},{"key":"2020021215282454700_R58","unstructured":"Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinicians. Toronto: Little, Brown and Co; 1991."},{"key":"2020021215282454700_R59","doi-asserted-by":"crossref","unstructured":"Mulrow CD. Rationale for systematic reviews. BMJ. 1994;309:597\u2013599.","DOI":"10.1136\/bmj.309.6954.597"},{"key":"2020021215282454700_R60","doi-asserted-by":"crossref","unstructured":"Meyer RM, Kouroukis CT. Understanding outcome measures. Evidence-based Oncol. 2001;2:172\u2013176.","DOI":"10.1054\/ebon.2001.0164"},{"key":"2020021215282454700_R61","doi-asserted-by":"crossref","unstructured":"Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin\u2019s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11:2258\u20132272.","DOI":"10.1200\/JCO.1993.11.11.2258"},{"key":"2020021215282454700_R62","doi-asserted-by":"crossref","unstructured":"Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin\u2019s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin\u2019s Disease Collaborative Group. J Clin Oncol. 1998;16:830\u2013843.","DOI":"10.1200\/JCO.1998.16.3.830"},{"key":"2020021215282454700_R63","doi-asserted-by":"crossref","unstructured":"Connors JM, Noordijk EM, Horning SJ. Hodgkin\u2019s lymphoma: basing the treatment on the evidence. Hematology (Am Soc Hematol Educ Program). 2001;178\u2013193.","DOI":"10.1182\/asheducation-2001.1.178"},{"key":"2020021215282454700_R64","doi-asserted-by":"crossref","unstructured":"Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin\u2019s disease. J Clin Oncol. 2001;19:4238\u20134244.","DOI":"10.1200\/JCO.2001.19.22.4238"},{"key":"2020021215282454700_R65","unstructured":"Hagenbeek A, Eghbali H, Ferme\u0301 C, et al. Three cycles of MOPP\/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I\u2013II Hodgkin\u2019s disease: preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients [abstract]. Blood. 2000;96:575a."},{"key":"2020021215282454700_R66","doi-asserted-by":"crossref","unstructured":"Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol. 2004; 22:2835\u20132841.","DOI":"10.1200\/JCO.2004.12.170"},{"key":"2020021215282454700_R67","unstructured":"Straus DJ, Yahalom J, Zelenetz AD, et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non bulky Hodgkin\u2019s disease [abstract]. Blood. 2001;98:769a."},{"key":"2020021215282454700_R68","unstructured":"Henry-Amar M, Aeppli DM, Anderson J, et al. Study of Second Cancer Risk. In Somers R, Henry-Amar M, Meerwaldt JK, Carde P, eds. Treatment Strategy in Hodgkin\u2019s Disease. London: John Libbey and Co; 1990:355\u2013379."},{"key":"2020021215282454700_R69","doi-asserted-by":"crossref","unstructured":"Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484\u20133494.","DOI":"10.1200\/JCO.2002.09.038"},{"key":"2020021215282454700_R70","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498\u2013509.","DOI":"10.1200\/JCO.2000.18.3.498"},{"key":"2020021215282454700_R71","doi-asserted-by":"crossref","unstructured":"Ng AK, Bernardo MVP, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100:1989\u20131996.","DOI":"10.1182\/blood-2002-02-0634"},{"key":"2020021215282454700_R72","doi-asserted-by":"crossref","unstructured":"van Leeuwen FE, Klokman WJ, van\u2019t Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adult. J Clin Oncol. 2000;18:487\u2013497.","DOI":"10.1200\/JCO.2000.18.3.487"},{"key":"2020021215282454700_R73","doi-asserted-by":"crossref","unstructured":"Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin\u2019s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435\u20132443.","DOI":"10.1200\/JCO.2000.18.12.2435"},{"key":"2020021215282454700_R74","doi-asserted-by":"crossref","unstructured":"Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin\u2019s disease. N Engl J Med. 1996;21;334:745\u2013751.","DOI":"10.1056\/NEJM199603213341201"},{"key":"2020021215282454700_R75","doi-asserted-by":"crossref","unstructured":"Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831\u20132837.","DOI":"10.1001\/jama.290.21.2831"},{"key":"2020021215282454700_R76","doi-asserted-by":"crossref","unstructured":"Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, van Putten WL, Levendag PC. Ischemic heart disease after mantlefield irradiation for Hodgkin\u2019s disease in long-term follow-up. Radiother Oncol. 1999;51:35\u201342.","DOI":"10.1016\/S0167-8140(99)00026-2"},{"key":"2020021215282454700_R77","doi-asserted-by":"crossref","unstructured":"Eriksson F, Gagliardi G, Liedberg A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin\u2019s disease: analysis with the relative seriality model. Radiother Oncol. 2000;55:153\u2013162.","DOI":"10.1016\/S0167-8140(00)00166-3"},{"key":"2020021215282454700_R78","doi-asserted-by":"crossref","unstructured":"Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin\u2019s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys. 2000;48:169.","DOI":"10.1016\/S0360-3016(00)00647-7"},{"key":"2020021215282454700_R79","doi-asserted-by":"crossref","unstructured":"Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin\u2019s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program). 2003;225\u2013247.","DOI":"10.1182\/asheducation-2003.1.225"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/184\/1634517\/184_202ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/184\/1634517\/184_202ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:29:48Z","timestamp":1581539388000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/184\/18699\/Hodgkins-Lymphoma-Evolving-Concepts-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.184","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}